652 related articles for article (PubMed ID: 25336717)
21. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation.
Gabriel MT; Calleja LR; Chalopin A; Ory B; Heymann D
Clin Chem; 2016 Apr; 62(4):571-81. PubMed ID: 26896446
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
Kelley RK; Magbanua MJ; Butler TM; Collisson EA; Hwang J; Sidiropoulos N; Evason K; McWhirter RM; Hameed B; Wayne EM; Yao FY; Venook AP; Park JW
BMC Cancer; 2015 Mar; 15():206. PubMed ID: 25884197
[TBL] [Abstract][Full Text] [Related]
24. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
[TBL] [Abstract][Full Text] [Related]
25. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
[TBL] [Abstract][Full Text] [Related]
26. MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment.
Lapin M; Tjensvoll K; Oltedal S; Buhl T; Gilje B; Smaaland R; Nordgård O
Sci Rep; 2016 Jul; 6():28929. PubMed ID: 27432216
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer.
Dirix L; Buys A; Oeyen S; Peeters D; Liègeois V; Prové A; Rondas D; Vervoort L; Mariën V; Laere SV; Vermeulen P
Breast Cancer Res Treat; 2022 Jun; 193(2):437-444. PubMed ID: 35397078
[TBL] [Abstract][Full Text] [Related]
28. Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer.
Ito M; Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Saito M
Med Oncol; 2019 Sep; 36(10):89. PubMed ID: 31520329
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
[TBL] [Abstract][Full Text] [Related]
30. Comparison of circulating tumor cell (CTC) detection rates with epithelial cell adhesion molecule (EpCAM) and cell surface vimentin (CSV) antibodies in different solid tumors: a retrospective study.
Gao Y; Fan WH; Song Z; Lou H; Kang X
PeerJ; 2021; 9():e10777. PubMed ID: 33717672
[TBL] [Abstract][Full Text] [Related]
31. Clonality of circulating tumor cells in breast cancer brain metastasis patients.
Riebensahm C; Joosse SA; Mohme M; Hanssen A; Matschke J; Goy Y; Witzel I; Lamszus K; Kropidlowski J; Petersen C; Kolb-Kokocinski A; Sauer S; Borgmann K; Glatzel M; Müller V; Westphal M; Riethdorf S; Pantel K; Wikman H
Breast Cancer Res; 2019 Sep; 21(1):101. PubMed ID: 31481116
[TBL] [Abstract][Full Text] [Related]
32. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
33. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.
Satelli A; Mitra A; Brownlee Z; Xia X; Bellister S; Overman MJ; Kopetz S; Ellis LM; Meng QH; Li S
Clin Cancer Res; 2015 Feb; 21(4):899-906. PubMed ID: 25516888
[TBL] [Abstract][Full Text] [Related]
34. Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells.
Sheng Y; Wang T; Li H; Zhang Z; Chen J; He C; Li Y; Lv Y; Zhang J; Xu C; Wang Z; Huang C; Wang L
Oncotarget; 2017 Jan; 8(5):8801-8806. PubMed ID: 28187533
[TBL] [Abstract][Full Text] [Related]
35. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
[TBL] [Abstract][Full Text] [Related]
36. Challenges in the enumeration and phenotyping of CTC.
Coumans FA; Ligthart ST; Uhr JW; Terstappen LW
Clin Cancer Res; 2012 Oct; 18(20):5711-8. PubMed ID: 23014524
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
39. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
[TBL] [Abstract][Full Text] [Related]
40. Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients.
Payne RE; Wang F; Su N; Krell J; Zebrowski A; Yagüe E; Ma XJ; Luo Y; Coombes RC
Br J Cancer; 2012 May; 106(11):1790-7. PubMed ID: 22538972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
